Cargando…

Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial

AIMS: Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation/atrial flutter (AF/AFL), it is im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vamos, Mate, Oldgren, Jonas, Nam, Gi-Byoung, Lip, Gregory Y H, Calkins, Hugh, Zhu, Jun, Ueng, Kwo-Chang, Ludwigs, Ulf, Wieloch, Mattias, Stewart, John, Hohnloser, Stefan H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175188/ https://www.ncbi.nlm.nih.gov/pubmed/34958366 http://dx.doi.org/10.1093/ehjcvp/pvab090

Ejemplares similares

Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study
por: Vamos, Mate, et al.
Publicado: (2019)

Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial
por: Blomström-Lundqvist, Carina, et al.
Publicado: (2023)

Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020)

Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter
por: Curtis, Anne B, et al.
Publicado: (2021)

Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
por: Torp-Pedersen, Christian, et al.
Publicado: (2011)

Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2020)

Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy
por: Wolbrette, Deborah, et al.
Publicado: (2010)

Correction to: Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter
Publicado: (2023)

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction
por: Christiansen, Christine Benn, et al.
Publicado: (2010)

Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
por: Naccarelli, Gerald V., et al.
Publicado: (2011)

Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial
por: Pisters, Ron, et al.
Publicado: (2014)

Dronedarone in patients with congestive heart failure: insights from ATHENA
por: Hohnloser, Stefan H., et al.
Publicado: (2010)

Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS‐ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2022)

The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
por: Naccarelli, Gerald V, et al.
Publicado: (2014)

Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter
por: Kim, Michael H., et al.
Publicado: (2014)

Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies
por: Thind, Munveer, et al.
Publicado: (2022)

Dronedarone in the management of atrial fibrillation
por: Saleem, TS Mohamed, et al.
Publicado: (2010)

Management of atrial fibrillation: focus on the role of dronedarone
por: Cheng, Judy WM
Publicado: (2011)

Ehrlichiosis-Induced Atrial Flutter: An Unusual Cause of Atrial Flutter
por: Kunnumpurath, Anthony, et al.
Publicado: (2020)

Dronedarone for atrial fibrillation: a new therapeutic agent
por: Patel, Pawan D, et al.
Publicado: (2009)

Cost considerations in the management of atrial fibrillation – impact of dronedarone
por: Khaykin, Yaariv, et al.
Publicado: (2012)

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
por: Trigo, Paula, et al.
Publicado: (2012)

Elevated liver enzymes associated with dronedarone for atrial fibrillation
por: Ragucci, Kelly R
Publicado: (2013)

Dronedarone-induced Phototoxicity in a Patient with Atrial Fibrillation
por: Datar, Praveen, et al.
Publicado: (2019)

Restoration of Atrial Mechanical Function after Successful Radio-Frequency Catheter Ablation of Atrial Flutter
por: Rhee, Kyoung-Suk, et al.
Publicado: (2001)

Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation
por: Saengklub, Nakkawee, et al.
Publicado: (2017)

Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis
por: Vamos, Mate, et al.
Publicado: (2016)

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
por: Heijman, Jordi, et al.
Publicado: (2013)

Electrophysiological Mechanisms of Atrial Flutter
por: Tai, Ching- Tai, et al.
Publicado: (2006)

Atrial flutter with atypical presentation
por: Kataria, Vikas, et al.
Publicado: (2016)

Fetal Atrial Flutter Associated with Atrial Septal Aneurysm
por: Tongprasert, Fuanglada, et al.
Publicado: (2022)

Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model
por: Reynolds, Matthew R, et al.
Publicado: (2013)

Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation
por: Schweizer, Patrick A, et al.
Publicado: (2011)

Addressing the management of atrial fibrillation – a systematic review of the role of dronedarone
por: Podda, Gian Marco, et al.
Publicado: (2012)

Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation
por: Sullivan, Renee M, et al.
Publicado: (2010)

Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone
por: Chahal, C Anwar A, et al.
Publicado: (2012)

Cost-Effectiveness of Dronedarone and Amiodarone for the Treatment of Chinese Patients With Atrial Fibrillation
por: Zhang, Mengran, et al.
Publicado: (2021)

Amiodarone vs Dronedarone for Atrial Fibrillation: A Retrospective Cohort Study
por: Brophy, James M., et al.
Publicado: (2022)

Gap-related Pulmonary Vein and Left Atrial Flutter Mimicking Cavotricuspid Isthmus-dependent Atrial Flutter
por: Komaki, Tomo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_khff41fevgcbg6q852iqsvjp5q